Pedro Martinez-Clark, MD
Interventional Cardiology · Miami, FLNPI 1205933504
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (40.3%), other and food and beverage — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 75.7% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2021 at $39,711 and has fallen 83.1% since, to $6,699 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 597 payments — averaging $228.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$103K
- Medtronic$12K
- Abbott$8K
- Alnylam Pharmaceuticals Inc.$1K
- Bard Peripheral Vascular, Inc.$1K
- Biotronik Inc.$971
- plus $10K from 45 others
Across 161 payments — averaging $9993.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GE HealthCare$875K
- Boehringer Ingelheim$322K
- Alnylam Pharmaceuticals Inc.$195K
- Pfizer$69K
- Vifor (international) Ltd.$52K
- Janssen Research & Development, LLC$42K
- plus $54K from 4 others
What the payments were for
- Speaking & faculty fees$5,0004%
- Travel & lodging$8,2576%
- Food & beverage$22,76617%
- Education$54,90540%
- Other$45,45033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$57,202
- VenaCure 1470 Pro$24,631
- Auryon$10,500
- EVLT$9,600
- Resolute$7,105
- Mitra Clip system$5,377
- OPTIMIZER$732
- CROSSER$340
- VENOVO$335
- Quadra Allure MP RF CRT Pacemkr$287
- MitraClip System$270
- MitraClip$269
- Varithena Administration Pack$265
- Trifecta GT Tissue Heart Valve$263
- AlphaVac$249
- CAMZYOS$242
- HawkOne$228
- Micra$215
- AZURE XT DR MRI SURESCAN$180
- Confirm Rx$170
How this compares
$136,378 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 409 | $427,454 |
| EntrestoSacubitril/Valsartan | 321 | $369,487 |
| XareltoRivaroxaban | 250 | $261,858 |
| FarxigaDapagliflozin Propanediol | 228 | $231,259 |
| BrilintaTicagrelor | 186 | $154,116 |
| JardianceEmpagliflozin | 70 | $82,115 |
| OzempicSemaglutide | 51 | $47,808 |
| Repatha SureclickEvolocumab | 34 | $31,261 |
| Repatha SyringeEvolocumab | 34 | $30,340 |
| VerquvoVericiguat | 12 | $13,602 |
| InpefaSotagliflozin | 15 | $11,892 |
| DapagliflozinDapagliflozin Propanediol | 21 | $10,024 |
| Nifedipine ErNifedipine | 350 | $6,478 |
| Ranolazine ErRanolazine | 51 | $5,770 |
| Atorvastatin Calcium | 673 | $4,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $418 | $427,454409 claims |
| AstraZenecaFarxiga, Brilinta | $883 | $385,375414 claims |
| NovartisEntresto | $530 | $369,487321 claims |
| Johnson & JohnsonXarelto | $725 | $261,858250 claims |
| Boehringer IngelheimJardiance | $474 | $82,11570 claims |
| Novo NordiskOzempic | $119 | $47,80851 claims |
| MerckVerquvo | $422 | $13,60212 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $186 | $11,89215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Eduardo de MarchenaMiami$498K
- Juan ZambranoMiami$173K
- Michael DyalMiami$157K
- Nish PatelMiami$149K
- Mauricio CohenMiami$129K
- Marquand PattonMiami$112K
- Ramon QuesadaMiami$94K
- Alvaro GomezMiami$71K
- Vinod ChainaniMiami$69K
- Arthur LeeGainesville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.